The aim of this project, which was commissioned by NICE through the NIHR HTA Programme as part of the NICE’s Single Technology Appraisal process, was to review the evidence for the clinical and cost-effectiveness of Secukinumab for treating moderate to severe plaque psoriasis. The clinical evidence submitted by the company (Novartis) responsible for manufacturing Secukinumab (Cosentyx) consisted of four phase III RCTs comparing Secukinumab with placebo and a dose-response trial. The Aberdeen HTA Group acted as the Evidence Review Group (ERG) for the project and provided an independent critique of the clinical and cost-effectiveness evidence submitted by the company.

After taking into consideration the company submission and the findings of the ERG’s critique, NICE released clinical guidance (TA350, July 2015). Secukinumab is currently recommended as an option for treating people with plaque psoriasis if (i) the disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index of more than 10; (ii) the disease has failed to respond to standard systemic therapies, for example, ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or these treatments are contraindicated or the person cannot tolerate them; (iii) the company provides it with the discount agreed in the patient access scheme. Secukinumab treatment should be stopped in people whose psoriasis has not responded adequately at 12 weeks.

For further information:


Miriam Brazzelli:




Cummins, E, Scott, N, Cruickshank, M, Fraser, C, Ormerod, A, Brazzelli, M. Secukinumab for treating moderate to severe plaque psoriasis. Evidence Review Group report in support of the NICE STA Programme. University of Aberdeen: Health Services Research Unit; 2015. URL: